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Abstract
Background: Human hookworm infection is a major cause of anemia and malnutrition of adults
and children in the developing world. As part of on-going efforts to control hookworm infection,
The Human Hookworm Vaccine Initiative has identified candidate vaccine antigens from the
infective L3 larval stages and adult stages of the parasite. Adult stage antigens include the cytosolic
glutathione-S-transferases (GSTs). Nematode GSTs facilitate the inactivation and degradation of a
variety of electrophilic substrates (drugs) via the nucleophilic addition of reduced glutathione.
Parasite GSTs also play significant roles in multi-drug resistance and the modulation of host-
immune defense mechanisms.
Results:  The crystal structures of Na-GST-1 and Na-GST-2, two major GSTs from Necator
americanus the main human hookworm parasite, have been solved at the resolution limits of 2.4 Å
and 1.9 Å respectively. The structure of Na-GST-1 was refined to R-factor 18.9% (R-free 28.3%)
while that of Na-GST-2 was refined to R-factor 17.1% (R-free 21.7%). Glutathione usurped during
the fermentation process in bound in the glutathione binding site (G-site) of each monomer of Na-
GST-2. Na-GST-1 is uncomplexed and its G-site is abrogated by Gln 50. These first structures of
human hookworm parasite GSTs could aid the design of novel hookworm drugs.
Conclusion: The 3-dimensional structures of Na-GST-1 and Na-GST-2 show two views of human
hookworm GSTs. While the GST-complex structure of Na-GST-2 reveals a typical GST G-site that
of Na-GST-1 suggests that there is some conformational flexibility required in order to bind the
substrate GST. In addition, the overall binding cavities for both are larger, more open, as well as
more accessible to diverse ligands than those of GSTs from organisms that have other major
detoxifying mechanisms. The results from this study could aid in the design of novel drugs and
vaccine antigens.
Published: 26 June 2007
BMC Structural Biology 2007, 7:42 doi:10.1186/1472-6807-7-42
Received: 9 February 2007
Accepted: 26 June 2007
This article is available from: http://www.biomedcentral.com/1472-6807/7/42
© 2007 Asojo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
Page 2 of 11
(page number not for citation purposes)
Background
In 1962, Dr. Norman Stoll of the Rockefeller foundation
referred to human hookworm infection ('hookworm') as
the "The Great Infection of Mankind" and today, almost
half a century later, this remains the case [1]. Hookworm
is still highly endemic globally, with approximately 576
million cases [2]. Necator americanus is considered the
most common hookworm worldwide. In the developing
regions of sub-Saharan Africa, Asia, and the Americas,
hookworm is an important cause of iron-deficiency ane-
mia and protein malnutrition; it is considered the second
most important parasitic disease next to malaria [1]. Both
of these pathologic processes result from the blood-feed-
ing activities of adult hookworms in the host small intes-
tine. It is estimated that approximately 25 adult N.
americanus hookworms cause the loss of approximately 1
ml of blood daily [3]. Two populations are particularly
vulnerable to developing hookworm anemia – children
and women of reproductive age, including pregnant
women [4]. In children, chronic hookworm anemia
results in impaired growth and cognitive development
[4], and a recent economic analysis suggests that these
processes result in significant wage earning losses [5]. In
pregnant women, hookworm is a major contributor to
severe anemia in pregnancy, low birth weight, and
increased maternal morbidity and mortality [6].
In response to the increasing awareness of hookworm as a
major public health threat, the World Health Organiza-
tion and other international agencies currently advocate
global efforts to control hookworm morbidity through
the regular and periodic use of anthelmintics [7]. In areas
of high hookworm transmission it is recommended to
administer anthelmintics, usually a single dose of either
albendazole or mebendazole, two-three times annually.
Although this 'deworming' approach would lead to
important morbidity reduction, there are larger concerns
about its sustainability given 1) the high rates of hook-
worm re-infection following drug treatment [8], 2) the
diminishing efficacy of the drug with repeated use [9],
possibly because of drug resistance [10], and 3) the high
prevalence and intensity of hookworm infection among
adult populations, most notably women of reproductive
age [11].
In response to these concerns, an international product
development partnership known as The Human Hook-
worm Vaccine Initiative [12] was initiated to develop an
anti-hookworm vaccine aimed at reducing worm burdens
and intensity, as an alternative or complementary
approach to deworming [1,13,14]. The HHVI has identi-
fied promising vaccine candidates from both the adult
stages of hookworms, as well as the infective larval stages
[13,15]. Ultimately, the HHVI is working to develop mul-
tivalent vaccine comprised of at least one larval and one
adult antigen. The larval antigen, ASP-2, pdb-code 1U53
[16], has undergone pilot scale manufacture, and Phase 1
clinical testing [13], while two adult antigens, including
an aspartic protease (APR-1) [17] and a glutathione-S-
transferase (GST) [18] are at earlier stages of development.
The GST superfamily is comprised of widely distributed
isoenzymes that perform functions as diverse as the
detoxification of electrophilic compounds to protecting
against peroxidative damage [19]. GSTs are homodimers
that catalyze the nucleophilic addition of reduced glutath-
ione to various diverse electrophilic substrates conse-
quently facilitating their inactivation, and extrusion
[20,21]. GSTs are a major detoxification system for
helminths, which have limited detoxification enzymes
and apparently lack the cytochrome P-450 dependent
reactions [22-24]. Thus, GSTs are critical to the survival of
adult helminths in the host. Inhibition of GSTs will
deprive parasitic helminths of their major detoxification
and defense against oxidative stress, making hookworm
GSTs a viable target for the design of novel vaccines as well
as anthelmintics. A 28 kDa GST from Schistosoma haema-
tobium, the etiologic agent of urinary schistosomiasis is
undergoing clinical trials in Africa [25].
In preclinical studies conducted in laboratory dogs and
hamsters challenged with infective hookworm larvae, Ac-
GST-1, a GST from the canine hookworm, Ancylosotma
caninum  demonstrated promise as vaccines that reduce
adult worm burden and fecundity of female worms [18].
Based on these laboratory animal vaccine trials, enzymatic
and structural studies were initiated recently to provide
new insights into the roles of hookworm GSTs as func-
tional vaccines. In order to clarify the role of hookworm
GSTs as possible drug and vaccine targets, we have under-
taken X-ray structural analysis of the Na-GST-1 and Na-
GST-2, two of the three known GSTs from N. americanus.
We present here first structures of human hookworm
GSTs.
Results and discussion
Crystallization and structure determination
The structures of two major GSTs, Na-GST-1 and Na-GST-
2 from Necator americanus, have been determined using
recombinant protein expressed in and secreted by Pichia
pastoris. Both Na-GST-1 and Na-GST-2 crystals were
obtained from solutions containing a high percentage of
polyethylene glycol. The best crystals were obtained by
vapor diffusion in sitting drop comprised of equal vol-
umes of 18 mg/ml protein and precipitant solution. Pre-
cipitant solutions were comprised of 0.1 M sodium
acetate pH 4.6 and 30% PEG 400 for Na-GST-1. The pre-
cipitant solution for Na-GST-2 was 18% PEG4000, 0.1125
M HEPES pH 7.55, 11.25% isopropanol, 0.01 M sodium
acetate and 0.06 M sodium citrate, to yield a final pH ofBMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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7.25. The statistics for data collection and refinement are
shown in Table 1.
Initial phases were obtained by molecular replacement
(MR) using the program PHASER [26-31] with a poly-
alanine model based on a monomer of HpolGST from the
nematode H. polygyrus (pdb code 1TW9) as the search
model [32]. The cell constants and space groups were a =
50Å, b = 81Å, c = 201Å, P212121 for Na-GST-1 and a = 58Å,
b = 108Å, c = 167Å β = 90.02°, P21 for Na-GST-2. The
orthorhombic Na-GST-1 contains a tetramer per asym-
metric unit which corresponds to a Matthews' coefficient
of 2.3 Å/Da and solvent content of 46%. Monoclinic Na-
GST-2 contains an octamer in the asymmetric unit, corre-
sponding to a Matthews' coefficient of 2.8 Å/Da and sol-
vent content of 55%.
Although the data set for Na-GST-2 could be processed as
orthorhombic and a molecular replacement solution
could be obtained in the space group P2221 having 4
monomers in the asymmetric unit, refinement stalled at
the unreasonably high R-factor of 50% (R-free 55%). In
an effort to confirm the space group, we generated a new
search model from a monomer of the structure of Na-
GST-2 that had been refined in the monoclinic space
group. Using this search model, we repeated PHASER in
the automatic mode with each of the alternative primitive
orthorhombic space groups. A molecular replacement
solution with reasonable packing was obtained in P2221
having 4 monomers in the asymmetric unit, and the same
rotation and translational function as with the poly-
alanine search model. However, despite having 2Fo-Fc
maps that agreed well with the model, both the R-factors
and free R-factors remained above 48% even after exten-
sive positional refinement with CNS, and/or REFMAC,
taking advantage of extensive non crystallographic sym-
metry (NCS). Simulated annealing with CNS in either
carthesian or torsional mode at the following tempera-
tures 2500 K, 5000 K, or even 10,000 K did not reduce the
free R-factor while the R-factor did not drop below 35%.
The inability to refine the model in the orthorhombic
space group, suggests that the space group is indeed mon-
oclinic P21. Furthermore, no other orthorhombic space
groups yielded a molecular replacement solution with
reasonable packing and no overlaps.
The final refined monoclinic P21 model of Na-GST-2 indi-
cates that differences in subunit structures prevent the
higher order symmetry, and there are differences in side
chain orientation across the monomers, and main chain
residues; both termini; G-site vicinity (33–45); as well as
in proximity to the dimerization domain (residues 101–
156, 172–183) which are capable of breaking the higher
order symmetry (Fig. 1). Overall the monomers of Na-
Table 1: Data Collection and model refinement statistics
Data Collection Na-GST-1 Na-GST-2
Space group P212121 P21
Resolution (Å) 30–2.4 (2.5–2.4) 30–1.9 (2.0–1.9)
Rmerge (%)a 6.0 (19.1) 6.0 (36.0)
Completeness (%) 97.7 (88.1) 88.0 (69.8)
Redundancy 5.3 (3.2) 2.9 (2.1)
I/σ(I) 11.2 (4.5) 12.1 (2.5)
Refinement
R-factorb (%) 18.9 (17.4) 17.6 (21.8)
R-freec (%) 28.3 (33.1) 21.7 (30.2)
Correlation coefficient
Fo – Fc 0.902 0.958
Fo – Fc Free 0.945 0.936
R.m.s. deviation
bond length (Å) 0.017 0.014
bond angles (°) 1.675 1.383
Ramachandran plot
Most preferred (%) 91.0 93.7
Additional allowed (%) 7.8 5.7
Generously allowed (%) 0.8 0.6
Disallowed (%) 0.4 0.0
Model Composition asymmetric unit
Number of monomers 4 8
Number of glutathione bound 0 8
a Rmerge = (Σ|I - <I>|)/ΣI, Where I is the observed intensity, and <I> is the average intensity obtained from multiple observations of symmetry-
related reflections after rejections.
bR-factor = Σ||Fo| - |Fc||/Σ|Fo| where Fo are observed and Fc are calculated structure factors amplitudes.
c R-free set uses 5% of randomly chosen reflections.BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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GST-2 align better than those of Na-GST-1 with r.m.s.
deviation of 0.16 Å versus 0.38 Å for all main chain atoms.
In both structures the largest variation is observed in the
regions bordering the G-site and anchoring the dimeriza-
tion domain (Fig. 1). These regions were previously
observed to be the regions of highest variation in the only
other known hookworm GST structure, that of HpolGST
from the nematode H. polygyrus (pdb code 1TW9) [32].
The final models for both Na-GST-2 and Na-GST-1 struc-
tures were obtained following iterative cycles of model
building in O [33] and structure refinement in REFMAC-
5 with NCS averaging [34-36]. Na-GST-1 was refined to R-
factor 18.9% (R-free 28.3%) at 2.4 Å, while Na-GST-2 was
refined to R-factor 17.1% (R-free 21.7%) at 1.9 Å.
All the main chain atoms for all 206 amino acids for all
monomers were ordered in the Na-GST-1 structures how-
ever some monomers have disordered side chain residues,
most prominently in the region from amino acids 105
through 132, interestingly these residues are include some
of those that break the higher order symmetry of the Na-
GST-2 structure. In the Na-GST-2 structure, all main chain
and side chain atoms for each monomer were visible in
2Fo-Fc omit maps calculated from the molecular replace-
ment solutions.
The main chain and side chain stereochemistry of the
refined models are excellent and 98% of main chain phi/
psi angles lie within the allowed region of a Ramachan-
dran plot. More details of the quality of the structure as
well as data collection are shown in Table 1. The atomic
coordinates and structure factors have been deposited in
the PDB under accession numbers 2ON5 and 2ON7 for
Na-GST-2 and Na-GST-1 respectively.
Structural features
The final refined model of Na-GST-1 has four monomers
in the asymmetric unit, while Na-GST-2 has eight mono-
mers in the asymmetric unit. As is the case with all GSTs,
both Na-GST-1 and Na-GST-2 form dimers. The funda-
mental/active units of both structures are homodimers
with the classical GST topology of Nu class nematode spe-
cific GSTs (Fig 2). Each monomer of the homodimer is
related by a 2-fold axis of symmetry. The highly conserved
N-terminal glutathione binding site is embedded within
an alpha-beta domain while the more variable C-terminal
ligand binding site is in the helical alpha domain (Fig. 2).
The primary and tertiary structures of Na-GST-1 are more
like that of HpolGST than Na-GST-2 (Fig. 3). Na-GST-1
has higher sequence similarity with HpolGST than Na-
GST-2 67% versus 61% the same goes for r.m.s deviation
0.84 Å versus 0.91 Å, for all main chain atoms. However,
the monomers and dimers are also quite similar to that of
Structural alignment of the a) four Na-GST-1 molecules and b) eight Na-GST-2 molecules in the crystallographic asymmetric  unit, colored in rainbow from blue (N-termini) to red (C-termini) Figure 1
Structural alignment of the a) four Na-GST-1 molecules and b) eight Na-GST-2 molecules in the crystallographic asymmetric 
unit, colored in rainbow from blue (N-termini) to red (C-termini). Side-chains in the regions of greatest variation are shown as 
sticks.BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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human GST such as represented by hematopoietic pros-
tagladin D synthase (HsGST) [37] (Fig. 3. & Fig. 4). Na-
GST-1 has lower sequence similarity with HsGST than Na-
GST-2 34% versus 38% but higher r.m.s deviation for
alignment of dimers is 1.592 Å versus 1.434 Å, for all
main chain atoms. Interestingly the regions of highest var-
iability are along the dimer interface, most notably from
helices α4 and α5 as well as the relative orientation of
helix α8 (Fig. 4). The variation in these regions leads to a
considerably difference in the size of binding cavity and
accessibility to said cavity of the GSTs (Fig. 4). Large por-
tions of the loop linking helices α4 and α5 are disordered
in the HpolGST structure. The structures reveal that in the
Nu class nematode specific GSTs the monomers form a
more open embrace around the binding cavity, as com-
pared to human GST, resulting in wider cavities that are
more accessible to larger compounds. This is inline with
the role of these GSTs as the major detoxification mecha-
nism for the hookworm parasite. Furthermore, the cavity
is more open in the absence of glutathione (in the case of
Na-GST-1) than with glutathione bound (in the case of
Na-GST-2), suggesting a conformational variation upon
glutathione binding.
G-site features
Although no glutathione was added to the crystallization
mixture, unambiguous density for a glutathione molecule
was observed in G-site of each monomer of Na-GST-2
(Fig. 5). Apparently, Na-GST-2 usurps glutathione during
the fermentation process. No such density was observed
in the electron density maps for Na-GST-1, instead scat-
tered density were visible in the substrate binding cavity
(Fig. 5). Interestingly, the G-site of Na-GST-1 cannot fit
glutathione as it is abrogated by Gln 50 which points
directly in the binding cavity blocking glutathione bind-
ing. A rotation of Gln around the Cβ will allow sufficient
room for gluthatione to bind. It is plausible that a pH
change may facilitate this rotation. Na-GST-1 was crystal-
lized at an acidic pH 4.6 whereas Na-GST-2 was crystal-
lized at a more basic pH of 7.5. Evidently, Na-GST-1 is
capable of binding glutathione and like Na-GST-2 is cata-
lytically active at pH 6.8 as measured by glutathione con-
jugation with 1-chloro-2, 4-dinitrobenzene (CDNB)
[38,39].
As was observed in other GSTs, the conserved, catalytic Tyr
(Tyr 8) stabilizes the Cys moiety of glutathione. Tyr 8
forms a hydrogen bond with the sulfur of glutathione. The
formation of this hydrogen bond interaction may result in
a lower pKa for the thiol in the GST-glutathione complex
[40,41]. The main chain oxygen and nitrogen of Ile 51
form hydrogen bonds with the nitrogen and oxygen of the
Cys of glutathione (Fig. 5). The side chain glutamyl resi-
dues of glutathione face the inter-domain cleft and are sta-
bilized by hydrogen bonds with Trp 39 (Fig. 5). Trp 39 is
conserved in sigma class of GSTs, typified by hematopoi-
etic prostagladin D synthase [37] whereas Na-GST-1 like
another Nu class GST HpolGST has a Phe in that position.
Phe 39 is incapable of forming the same type of hydrogen
bond however Lys 43 is in close enough proximity to form
the same interaction as Trp 39. In addition, the glycyl res-
idue in glutathione forms hydrogen bonds with Ser 64,
while having an inter-molecular hydrogen bond from the
conserved Asp 97 from across the dimer interface (Fig. 5).
Our Na-GST-2 structure gives the first view of glutathione
binding in a Nu class GST [32].
H-site features for Nu class GSTs
Ligand binding or H-sites structures vary across classes of
GSTs because the C-terminal H-sites are largely responsi-
ble for the varying substrate specificities of the GSTs. As
was observed in the structure of HpolGST, the H-site of
Nu class GSTs as represented by Na-GST-2 forms a long,
deep cleft (Fig. 6). This cleft is formed by the interaction
between hydrophobic residues Gly 13, Ala/Leu 14, Leu/
Phe 65 from the α3 domain with the residues Tyr 95, Phe/
Tyr 106 and Phe 206 from the α/β domain. There is an
additional stabilizing salt bridge from Glu 162 to Arg 201
(Fig 6). In the Na-GST-2 structure there are some ethylene
glycol molecules from the cryoprotectant solution lining
the surface of the H-site (Fig. 6). The significance of the
ethylene glycol molecules remains unclear until we probe
the H-site with a suitable ligand. The primary and tertiary
structures of the H-sites of the Nu class GSTs overlay quite
well (Fig. 3). Na-GST-1 and Na-GST-2 as was observed for
HpolGST [32] exhibit H-sites or ligand binding sites that
are larger and more receptive to longer, larger inhibitors
which cannot fit in the smaller H-site of mammalian GST
(Fig. 7). Overlaying of the cavities reveals the considerable
Ribbon representation of Na-GST-2 dimer reveals a typical  GST dimer Figure 2
Ribbon representation of Na-GST-2 dimer reveals a typical 
GST dimer.BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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reduction in the active site size between sigma class and
nu class (Fig. 7). This, in addition to the more open and
accessible binding cavity (Fig. 4) suggests that it is possi-
ble for the GSTs to play the role of the major detoxifying
system in the hookworm parasite.
Drug inhibition and implications for drug design
We examined if conventional anthelmintics were capable
of competitively inhibiting the hookworm GSTs by meas-
uring the conjugation of CDNB with glutathione. We then
compared our activity data to that of model roundworm
Ascaris suum (As-GST-1) which used the same assay and
conditions as we did [42]. Like hookworms, tapeworms
are treated with albendazole or mebendazole. Our results
show that albendazole has approximately 5 times lower
IC50 for Na-GST-1 and 7 times lower IC50 for Na-GST-2
than As-GST-1, Table 2. The crystal structure of As-GST-1
has not been solved but comparing the primary sequence
of  As-GST-1 with the Nu class GSTs reveals a high
sequence similarity even in the C-terminus alpha domain
(Fig. 3a), suggesting similar substrate specificity and lig-
and binding. However, As-GST-1 some large residues
which may obscure the H-site (Lys 183, Lys 203 and Trp
167), accounting for the higher IC50.
The IC50 for both albendazole and chlorotriphenyltin
were higher for Na-GST-1 than Na-GST-2 (Table 2). Chlo-
rotriphenyltin was the most effective inhibitor of Na-GST-
1, Na-GST-2 as well as As-GST-1. This is not surprising
based on the relatively small size of chlorotriphenyltin
compared to albendazole. Chlorotriphenyltin success-
fully competes with CDNB for glutathione conjugation as
it is more likely to have access to the H-site, than albenda-
zole, however it is doubtful that chlorotriphenyltin is spe-
cific for any class of GSTs. In order to clarify the mode of
drug binding, we are currently attempting to co-crystallize
both hookworm GSTs with albendazole or chlorotriphe-
nyltin.
Neither Na-GST-1 and Na-GST-2 are effectively inhibited
by praziquantel, however, praziquantel is a broad spec-
trum anthelmintic and is the leading drug for the treat-
ment of schistosomiasis. The structure of the SjGST from
Schistosoma japonica in complex with praziquantel has
been solved and in this structure, praziquantel appears to
bind in the G-site [43]. It was also observed that praziqu-
antel does not competitively inhibit recombinant SjGST
[44], suggesting that SjGST is not the target of praziquan-
tel as was speculated by McTigue and colleagues [43]. In
Sequence and structural alignment of Nu class GSTs with a Sigma Class GST (HsGST, human GST or hematopoietic prostagla- din D synthase [37]) and other parasite GSTs (SjGST, Schistosoma japonica [43], Ascaris suum (As-GST-1) [42] Figure 3
Sequence and structural alignment of Nu class GSTs with a Sigma Class GST (HsGST, human GST or hematopoietic prostagla-
din D synthase [37]) and other parasite GSTs (SjGST, Schistosoma japonica [43], Ascaris suum (As-GST-1) [42]. (a) The alignment 
reveals that firstly N-terminal alpha beta domain is more conserved than the C-terminal alpha domain. Furthermore, Na-GST-
1 has higher sequence identity with HpolGST than Na-GST-2 and the lowest similarity is with the HsGST. This figure was gen-
erated with ESPript [55, 56]. (b) Structural alignment of monomers of Nu class GSTs (Na-GST-1, magenta; Na-GST-2, gold; 
HpolGST, green) with a sigma class GST (HsGST, cyan).BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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fact based on our data we may conclude that neither Na-
Comparison of GST dimers Figure 4
Comparison of GST dimers. a) Superposition of GST dimers reveals that they are very similar, however, Nu class (Na-GST-1, 
magenta; Na-GST-2, gold; HpolGST, green) have a more accessible binding cavity than sigma class (HsGST, cyan). The path to 
the binding cavity is indicated by the red arrow. The surface plots of Nu class GSTs b) HpolGST c) Na-GST-1 d) Na-GST-2 
reveal larger access way to binding cavity than e) sigma class GST (HsGST).
G-site features Figure 5
G-site features. a) G-site of Na-GST-2 shows unambiguous electron density for glutathione (GTT) in 2Fo-Fc maps contoured 
at 1 sigma. b) No such density is visible in the G-site of Na-GST-1. c) Alignment of G-sites of Na-GST-2 and Na-GST-1. GTT is 
modeled from Na-GST-2 structure. The monomers of Na-GST-2 dimer are colored in cyan and green, while Na-GST-1 is 
colored in violet. Trp39 forms a hydrogen bond with glutathione in Na-GST-2 which is replaced with Phe39 in Na-GST-1. 
Gln50 is conserved in both Na-GST-2 and Na-GST-1, but the side chain is flipped such that glutathione cannot fit in Na-GST-1 
G-site. The catalytic Tyr8 maintains its conformation in both structures. Polar interactions and distances are also shown.BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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GST-1 nor Na-GST-2 is targeted by praziquantel.
Conclusion
The 3-dimensional structures of Na-GST-1 and Na-GST-2
are presented here. The GST-complex structure of Na-GST-
2 reveals a typical GST, while G-site that of Na-GST-1 is
abrogated by Gln 50 which suggests that some conforma-
tional flexibility is required in order to bind the substrate
GST. The overall binding cavities for both are larger, more
open and appear to be more accessible to diverse ligands
than those of GSTs from organisms that have other major
detoxifying mechanisms. Ongoing structural studies with
larger ligands are underway.
Methods
Molecular cloning and expression
A cDNA library of of N. americanus infective larvae (L3)
was constructed as previously described [45,46], cDNA
encoding  Na-GST-2 and Na-GST-1 were isolated by
immunoscreening of N. americanus L3 cDNA expression
library using antiserum against Ac-GST-1 from A. caninium
followed by cDNA cloning and sequencing [45]. The
entire coding sequence was PCR amplified from the first
strand cDNA of adult N. americanus with gene-specific
primers. The PCR products were sub-cloned into the
Pichia  expression vector pPICZαA (Invitrogen) via the
XhoI and XbaI sites. The correct insert and right reading
frame were confirmed by double strand sequencing of
recombinant plasmid using flanking vector primer: α-fac-
tor and 3' AOX1. Fermentation and large scale purifica-
tion were carried out according to the protocols described
H-site features Figure 6
H-site features. a) Stereo representation of the H-site of Na-GST-2, residues that form the cleft are shown as sticks. b) The C-
terminal loop of Na-GST-2 is stabilized by a network of hydrogen bonds, residues involved in these interactions are shown in 
as sticks, while the bonds are indicated by dashed lines and distances are shown. Residues are colored in rainbow representa-
tion from N-terminal to C-terminal (Blue-Green-Yellow-Orange-Red). Two ethylene glycol molecules (EDO, in cyan) from the 
cryo-protecting liquor are visible in the surface of the H-site.
a)                                                        b)
Table 2: Estimated inhibition constants of GSTs by conventional anthelmintics
Enzyme Na-GST-1 Na-GST-2 As-GST-1*
Inhibitor IC50 (μM) IC50 (μM) IC50 (μM)
Albendazole 87 68 520.0
Chlorotriphenyltin 22 0.7 0.3
Praziquantel (>20,000)** 3300 --
* Data from As-GST-1 is from reference [42]
** This was the maximum concentration tried due to solubility issues.BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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for Na-ASP-2 [47] and elsewhere (Goud et al. to be pub-
lished).
Crystallization and data collection
All crystals were grown at 22°C by vapor diffusion in sit-
ting drops. Both Na-GST-1 and Na-GST-2 was concen-
trated to 18 mg/mL in 100 mM Tris HCL pH 8.0, prior to
screening for crystallization conditions. Initial crystalliza-
tion screens were performed using the following commer-
cial screens from Nextal Biotechnologies (Qiagen)
Classics, PEG and Cryo. Single chunk-like Na-GST-1 crys-
tals were obtained from 0.1 M sodium acetate pH 4.6 and
30% PEG 400 (or 25% PEG MME 500). Initial Na-GST-2
crystals were flat, thin stacked plates which were smaller
than 0.03 mm on the smallest face. Following further
optimization using the Nextal OptiSalt pre-filled screens,
thicker rods were obtained in 18% PEG 4000, 0.1125 M
HEPES pH 7.55, 11.25% isopropanol, 0.01 M sodium
acetate pH 4.6, 0.06 M sodium citrate. Na-GST-1 crystals
were cryo-protected by adding 15% trehalose directly to
the drop. Na-GST-2 crystals were transferred to a cryo-pro-
tecting solution comprised of the precipitants and 20%
ethylene glycol prior to flash cooling. Crystals were flash
cooled in a stream of N2 (X-stream 2000 low temperature
system, RigakuMSC) prior to data collection. The X-ray
system consisted of RuH3R rotating anode generator
(RigakuMSC) operating at 50 kV and 100 mA, with Osmic
Micromax optics and an R-axis IV++ image plate detector
(RigakuMSC). Data were collected from a single crystal
using a crystal-to-detector distance of 200 mm and expo-
sure times of 20 minutes for 0.5° oscillations.
All X-ray data sets were collected using Crystal Clear
(d*trek) package [48]. Data was processed using MosFLM
[49,50]. The structures were solved by molecular replace-
ment with PHASER [26-31]. This was followed by iterative
cycles of manual model building with the program O [33]
and structure refinement with REFMAC5 [35,36] using a
maximum likelihood refinement procedure with Engh &
Huber Geometric parameters and free-R [51]. Data and
refined model statistics are shown in Table 1. The super-
position of models and r.m.s. deviations were calculated
using the program Swiss-PdbViewer Version 3.7 [52,53].
Unless otherwise noted, figures were generated using
pyMOL [54].
Activity studies
GST activity and drug inhibition was determined in a
standard assay measuring the conjugation of 1-chloro-2,
4-dinitrobenzene (CDNB) with glutathione [38,39]. The
assay mixture contained in a total of 1 mL, 1 mM CDND,
1 mM glutathione and 0.1 M potassium phosphate buffer,
pH 6.5. To determine GST activity, the rate of increase of
absorbance at 340 nm, were taken with a NanoDrop ND-
1000 Spectrophotometer every thirty seconds for 3 min-
utes upon initiation of the reaction by the addition of var-
ying concentrations of each enzyme.
Drug inhibition was measured using a fixed concentration
of enzyme (1 μM) and using concentration, from 1 nM to
20 mM, of the following compounds 1) albendazole (MP
Biomedicals), 2) praziquantel (Alexis) and 3) chlorot-
riphenyltin (Acros Organics) to inhibit in the glutathione
Nu class GSTs {a) Na-GST-2, c) HpolGST} have larger binding cavity than sigma class GST {b) HsGST} Figure 7
Nu class GSTs {a) Na-GST-2, c) HpolGST} have larger binding cavity than sigma class GST {b) HsGST}. d) Overlay of the cavi-
ties reveals the considerable reduction in the active site size between sigma class (blue) and nu class (cyan). The structure of 
HpolGST is missing a loop in close proximity to the binding cavity and we modeled it as cartoon from the Na-GST-2 structure. 
The glutathione in the G-site is shown as red stick model.   BMC Structural Biology 2007, 7:42 http://www.biomedcentral.com/1472-6807/7/42
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CNDB conjugation reaction. Water insoluble compounds
were dissolved in 100% ethanol. Absorbance readings, at
340 nm, were taken with a NanoDrop ND-1000 Spectro-
photometer every thirty seconds for 3 minutes upon initi-
ation of the reaction by the addition of 1 μM enzyme. The
50% enzymatic inhibitory concentrations (IC50) were
determined from direct plots of percent activity against
inhibitor concentration from data points generated from
at least 4 repetitions of each time point and concentration.
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